Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) EBITDA (2016 - 2025)

Tg Therapeutics has reported EBITDA over the past 10 years, most recently at $50.5 million for Q4 2025.

  • Quarterly results put EBITDA at $50.5 million for Q4 2025, up 864.48% from a year ago — trailing twelve months through Dec 2025 was $123.3 million (up 2194.4% YoY), and the annual figure for FY2025 was $123.3 million, up 2194.4%.
  • EBITDA for Q4 2025 was $50.5 million at Tg Therapeutics, up from $29.4 million in the prior quarter.
  • Over the last five years, EBITDA for TGTX hit a ceiling of $114.8 million in Q3 2023 and a floor of -$92.9 million in Q4 2021.
  • Median EBITDA over the past 5 years was -$23.7 million (2022), compared with a mean of -$20.7 million.
  • Biggest five-year swings in EBITDA: plummeted 89.17% in 2024 and later soared 864.48% in 2025.
  • Tg Therapeutics' EBITDA stood at -$92.9 million in 2021, then increased by 16.58% to -$77.5 million in 2022, then soared by 83.9% to -$12.5 million in 2023, then skyrocketed by 47.1% to -$6.6 million in 2024, then soared by 864.48% to $50.5 million in 2025.
  • The last three reported values for EBITDA were $50.5 million (Q4 2025), $29.4 million (Q3 2025), and $34.8 million (Q2 2025) per Business Quant data.